Helex Secures $1M for Kidney Gene Therapies

Helex, a biotechnology company specializing in genetic medicines for renal indications, has secured $1,000,000 in new investment from investors. This significant funding round will fuel the company’s mission to develop first-in-class therapies for kidney diseases, marking a crucial step in its growth trajectory. The company is pioneering an innovative approach to non-viral targeted delivery and genome editing specifically tailored for the kidney. Helex leverages its proprietary kidney tropic lipid nanoparticle delivery system in conjunction with the Epic-Cure(TM) 3D genome-based drug designer platform. This combined strategy aims to create a robust renal franchise of precise and scalable therapeutics. Its flagship program is a mutation-agnostic, potential one-and-done therapy for Autosomal Dominant Polycystic Kidney Disease (ADPKD), a debilitating genetic condition affecting over 4 million individuals worldwide. The $1,000,000 in capital raised is earmarked to accelerate Helex’s core research and development efforts. This investment is critical for advancing the company’s proprietary delivery technologies and its drug designer platform, which are fundamental to its therapeutic pipeline. Specifically, the funds will support further preclinical validation and optimization of its lead ADPKD asset, aiming to move it closer to clinical development and address the substantial unmet medical need in renal care. This funding round underscores investor confidence in Helex's scientific platform and its potential to deliver transformative treatments. With this infusion of capital, Helex is strategically positioned to expand its innovative pipeline, strengthen its research capabilities, and solidify its leadership in the burgeoning field of genetic medicines for kidney disease, ultimately striving to bring precise and effective therapies to patients globally.